Suzhou Alphamab Co., Ltd.

The 'Type 2 Diabetes - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights into 75+ companies and 80+ pipeline drugs for Type 2 Diabetes, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products. Key drugs include Eli Lilly's LY-3209590, Tonghua Dongbao's THDB0206, Rivus Pharmaceuticals' HU6, AstraZeneca's AZD5004, Sciwind Biosciences' XW014, and Suzhou Alphamab's KN056. The report highlights collaborations, mergers, acquisitions, and licensing activities, and assesses emerging trends and technologies in Type 2 Diabetes therapeutics.